IMATINIB RESISTANCE MUTATION ANALYSIS; IRMA

Imatinib is a Tyrosine kinase inhibitor (TKI) capable of inducing durable hematologic and cytologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develop functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage.

  • Test Type:
  • Pre-test Information:
    Submit latest BCR-ABL Quantitative report along with sample.
  • Report Delivery:
    Sample by Mon 11 am; Report Sat
  • Components:
    0

Sample Report

imatinib resistance mutation analysis in other Cities